SHA:688217 Revenue

In the year 2025, Shanghai Rightongene Biotechnology had annual revenue of 174.00M CNY, down -28.19%. Shanghai Rightongene Biotechnology had revenue of 34.90M in the quarter ending December 31, 2025, a decrease of -36.37%.

Revenue

174.00M

Revenue Growth

-28.19%

P/S Ratio

9.82

Revenue / Employee

433.91K

Employees

385

Market Cap

1.71B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	174.00M	-68.31M	-28.19%
Dec 31, 2024	242.31M	-15.91M	-6.16%
Dec 31, 2023	258.21M	-166.09M	-39.14%
Dec 31, 2022	424.30M	133.35M	45.83%
Dec 31, 2021	290.95M	6.03M	2.11%
Dec 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Shandong Sito Bio-technology	954.76M
Zhejiang East Asia Pharmaceutical	831.56M
Guiyang Xintian Pharmaceutical	755.34M
Jilin Jian Yisheng Pharmaceutical	639.10M
Hubei Goto Biopharm	626.28M
Tiansheng Pharmaceutical Group	516.17M
Sailong Pharmaceutical Group	244.84M
Shanghai Serum Bio-Technology	196.21M

Revenue Rankings